Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26718853 | 1.00 | PIK3CD (0.31) | PIK3CDSIGMAR1HTR2C | |
| SCHEMBL24171101 | 1.00 | PIK3CD (0.31) | PIK3CDSIGMAR1HTR2C | |
| SCHEMBL15132377 | 0.90 | NAMPT (0.32) | — | |
| SCHEMBL8222741 | 0.87 | PIK3CD (0.36) | PIK3CDSIGMAR1HTR2C | |
| SCHEMBL10093851 | 0.82 | — | — | |
| SCHEMBL20093533 | 0.81 | — | — | |
| SCHEMBL18640242 | 0.81 | SIGMAR1 (0.33) | SIGMAR1 | |
| SCHEMBL23583681 | 0.80 | HTR5A (0.33) | — | |
| SCHEMBL21516988 | 0.80 | GPR88 (0.35) | SIGMAR1 | |
| SCHEMBL18236910 | 0.76 | GPR88 (0.36) | PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208964-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | YUMANITY THERAPEUTICS, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240208964-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | YUMANITY THERAPEUTICS, INC. | 2024-06-27 | — | — | US | disclosed |
| WO-2024126777-A1 | HETEROAROMATIC COMPOUNDS | ASTRAZENECA AB (SE) | 2024-06-20 | — | — | WO | disclosed |
| WO-2023209084-A1 | CONDENSED BICYCLIC HETEROAROMATIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023209090-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AND THEIR APPLICATION IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2023-11-02 | — | — | WO | disclosed |
| EP-4268824-A1 | IMIDAZO[2,1-F][1,2,4]TRIAZINE DERIVATIVES USEFUL AS A MEDICAMENT | Manros Therapeutics (FR) | 2023-11-01 | — | — | EP | disclosed |
| US-20230271965-A1 | BICYCLIC HETEROARENES AND METHODS OF THEIR USE | YUMANITY THERAPEUTICS, INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230271965-A1 | BICYCLIC HETEROARENES AND METHODS OF THEIR USE | YUMANITY THERAPEUTICS, INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230150993-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-18 | — | — | US | disclosed |
| US-20230150993-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-18 | — | — | US | disclosed |
| US-20160151335-A1 | METHODS OF MODULATING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2016-06-02 | — | — | US | disclosed |
| US-20160145252-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-05-26 | — | — | US | disclosed |
| US-8653087-B2 | Pyrido [5, 4-D] pyrimidines as cell proliferation inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-8653087-B2 | Pyrido [5, 4-D] pyrimidines as cell proliferation inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-20120094975-A1 | PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
| US-20120094975-A1 | PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
| WO-2010026262-A1 | PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-11 | — | — | WO | disclosed |
| US-20090005447-A1 | METHODS, COMPOUNDS, AND COMPOSITIONS FOR REDUCING BODY FAT AND MODULATING FATTY ACID METABOLISM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-01-01 | — | — | US | disclosed |
| US-7423066-B2 | Dietetics; use in treatment of obesity, for reducing body weight, modulating body lipid metabolism, and reducing food intake | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-09-09 | — | — | US | disclosed |
| US-20080103209-A1 | Compounds And Methods For Treating Non-Inflammatory Pain Using Ppar Alpha Agonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103209-A1 | Compounds And Methods For Treating Non-Inflammatory Pain Using Ppar Alpha Agonists | FAAH, CNR2, FAAH2 | PIK3CD 2253/4885SIGMAR1 142/4885HTR2C 707/4885 |
| US-20090005447-A1 | METHODS, COMPOUNDS, AND COMPOSITIONS FOR REDUCING BODY FAT AND MODULATING FATTY ACID METABOLISM | LIPC, FABP4, FASN | PIK3CD 1365/4885SIGMAR1 2195/4885HTR2C 841/4885 |
| US-20160145252-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | PIK3CD 137/4885SIGMAR1 3383/4885HTR2C 4331/4885 |
| US-20240208964-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | PNPO, DPYD, PYGB | PIK3CD 3769/4885SIGMAR1 3986/4885HTR2C 928/4885 |
| US-20160151335-A1 | METHODS OF MODULATING CFTR ACTIVITY | CFTR, HSP90B1, SERPINB1 | PIK3CD 3062/4885SIGMAR1 2439/4885HTR2C 4230/4885 |
| US-20230271965-A1 | BICYCLIC HETEROARENES AND METHODS OF THEIR USE | NLN, GRIN2C, BCHE | PIK3CD 4563/4885SIGMAR1 1355/4885HTR2C 392/4885 |
| US-20230150993-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | MKI67, MCL1, CCNI | PIK3CD 1381/4885SIGMAR1 2922/4885HTR2C 4383/4885 |
| US-20120094975-A1 | PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS | CCNT1, CCNA1, CCND1 | PIK3CD 1916/4885SIGMAR1 1988/4885HTR2C 2276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.